{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:18:51Z","timestamp":1795105131436,"version":"4.10.3"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec id=\"ab-eoi260059-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Gene expression profiling (GEP) reliably predicts metastatic uveal melanoma risk and is used to manage uveal melanoma (UM) in patients with this diagnosis. Efforts to refine molecular prognostication continue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine if confirmatory cytopathology findings influence the prognostic accuracy of a commercially available GEP\/Preferentially Expressed Antigen in Melanoma (PRAME) assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The Collaborative Ocular Oncology Group 2 study, a prospective cohort study, was conducted from 2017 to 2020 with follow-up recorded at 6-month intervals. This was a multicenter study that included patients with choroidal and\/or ciliary body melanoma and results from a 15-GEP and PRAME RNA expression (15-GEP\/PRAME) assay. Patients with iris tumors or less than 6 months\u2019 follow-up were excluded. Study data were analyzed from April 2025 to July 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>15-GEP\/PRAME, cytopathology, and next-generation sequencing (NGS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Metastatic uveal melanoma rates in patients who had 15-GEP\/PRAME and confirmatory cytopathology (CCP) results confirming or suspicious for UM (GEP+CCP) were compared with those who had 15-GEP\/PRAME and no cytopathology performed, or unknown or nondiagnostic cytopathology results (GEP only). UM-associated variants identified by NGS were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1537 patients (mean [SD] age, 62.0 [13.4] years; 787 male [51.2%]), 727 (47.3%) had CCP results, and 810 (52.7%) had nondiagnostic cytopathology results or no cytopathology performed. Class 2\/PRAME+ tumors were more common (136 of 727 [18.7%]) in the GEP+CCP group than in the GEP-only group (72 of 810 [8.9%]; 9.8% difference; 95% CI, 6.4-13.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;.001), whereas class 1\/PRAME\u2013 tumors were less common (330 of 727 [45.4%] vs 495 of 810 [61.1%]; 15.7% difference; 95% CI, 10.8-20.6;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;.001). In patients with GEP+CCP, 22.7% (n\u2009=\u2009165) developed metastasis vs 15.4% (n\u2009=\u2009125) in patients with GEP only (7.3% difference, 95% CI, 3.3-11.2;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Adjusting for 15-GEP\/PRAME status, there were no differences in metastasis rates between CCP groups. Of 1327 patients with successful NGS, 94.1% (605 of 643) in the GEP+CCP group and 71.9% (492 of 684) in the GEP-only group had a UM-associated variant (22.2% difference, 95% CI, 18.3-26.0;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi260059-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Results of this cohort study reveal that no differences in metastasis outcomes were observed between patients with and without CCP within any GEP\/PRAME categories. UM-associated variants were found less frequently in the GEP-only group than in the GEP+CCP group. In this cohort, 15-GEP\/PRAME classification without CCP retained prognostic validity, supporting its clinical consideration in guiding metastatic surveillance in cases in which cytopathology is unavailable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2026.4378","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:30Z","timestamp":1792076430000},"page":"1032","source":"Crossref","is-referenced-by-count":0,"title":["Cytopathology and Prognostic Accuracy of 15-GEP\/PRAME"],"prefix":"10.1001","volume":"144","author":[{"given":"Anne Marie","family":"Lane","sequence":"first","affiliation":[{"name":"Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Schefler","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelia M.","family":"Correa","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute and Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Materin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H.","family":"Skalet","sequence":"additional","affiliation":[{"name":"Casey Eye Institute, Oregon Health and Science University, Portland"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisha D.","family":"Piggott","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Washington University, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Aaberg","sequence":"additional","affiliation":[{"name":"Retina Specialists of Michigan, Foundation for Vision Research, and Michigan State University College of Human Medicine, Grand Rapids"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Basil K.","family":"Williams","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute and Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[{"name":"Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C. N.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Sue Anschutz-Rodgers Eye Center, Department of Ophthalmology, University of Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devron","family":"Char","sequence":"additional","affiliation":[{"name":"Tumori Foundation, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Walter","sequence":"additional","affiliation":[{"name":"Retina Consultants, Hartford, Connecticut"},{"name":"Helen and Harry Gray Cancer Center, Hartford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Antonio","family":"Capone","sequence":"additional","affiliation":[{"name":"Associated Retina Consultants, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Desai","sequence":"additional","affiliation":[{"name":"New England Eye Center and Department of Ophthalmology, Tufts University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Tsai","sequence":"additional","affiliation":[{"name":"Retinal Consultants Medical Group, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[{"name":"Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill R.","family":"Wells","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Demirci","sequence":"additional","affiliation":[{"name":"Kellogg Eye Center, Department of Ophthalmology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cusick","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fuller","sequence":"additional","affiliation":[{"name":"Texas Retina Associates, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hovland","sequence":"additional","affiliation":[{"name":"Colorado Retina Associates, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Javid","sequence":"additional","affiliation":[{"name":"Retina Associates, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Altaweel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Wisconsin, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezekiel","family":"Weis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"},{"name":"Division of Ophthalmology, Department of Surgery, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reichstein","sequence":"additional","affiliation":[{"name":"Tennessee Retina, Nashville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Alabama, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Harbour","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas"},{"name":"Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana K.","family":"Kim","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi260059r1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2013).","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul Oncol Pathol"},{"issue":"12","key":"eoi260059r2","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"eoi260059r3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","article-title":"Evidence-based estimates of outcome in patients irradiated for intraocular melanoma.","volume":"120","author":"Gragoudas","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"24","key":"eoi260059r4","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma.","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"eoi260059r5","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study.","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"eoi260059r6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","article-title":"An accurate, clinically feasible multigene expression assay for predicting metastasis in uveal melanoma.","volume":"12","author":"Onken","year":"2010","journal-title":"J Mol Diagn"},{"issue":"8","key":"eoi260059r7","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multigene prognostic assay in uveal melanoma.","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"eoi260059r8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-1-62703-727-3","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile.","volume":"1102","author":"Harbour","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"28","key":"eoi260059r9","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1200\/JCO.24.00447","article-title":"15-Gene expression profile and PRAME as integrated prognostic test for uveal melanoma: first report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).","volume":"42","author":"Harbour","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"eoi260059r11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/24741264241302859","article-title":"Confirmatory cytopathology and potential impact on the predictive value of gene expression profiling in patients with uveal melanoma.","volume":"9","author":"Lane","year":"2024","journal-title":"J Vitreoretin Dis"},{"issue":"2","key":"eoi260059r12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00417-019-04531-8","article-title":"Multicenter analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4.","volume":"258","author":"Seider","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"eoi260059r13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1590\/S0004-27492013000200004","article-title":"Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy.","volume":"76","author":"Augsburger","year":"2013","journal-title":"Arq Bras Oftalmol"},{"issue":"1","key":"eoi260059r14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00417-013-2515-0","article-title":"Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic vs GEP classification in 159 patients, and relative prognostic significance of these classifications.","volume":"252","author":"Correa","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"eoi260059r10","unstructured":"National Comprehensive Cancer Network. Login page. Accessed July 26, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uveal.pdf"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2854985\/jamaophthalmology_lane_2026_oi_260059_1794515900.30499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:00:32Z","timestamp":1795104032000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2854985"}},"subtitle":["The Collaborative Ocular Oncology Group Study 2"],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.4378","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}